维生素K拮抗剂治疗中基因多态性与大出血风险:BLEEDS病例-队列研究
该研究在BLEEDS队列(16,570例VKA起始者)中采用病例-队列设计,分析CYP2C9、CYP4F2、GGCX及VKORC1基因变异与大出血的关联。结果显示CYP4F2-TT携带者大出血风险有升高趋势但未达统计学显著,而同时携带CYP4F2-TT与VKORC1-AA者风险显著增高(HR 6.7,95%CI 1.5-29.8),但此类多变异携带者中大出血病例数很少。
要点
- CYP4F2-TT携带者大出血风险较CC携带者呈1.6倍升高趋势,但未达统计学显著。
- 同时携带CYP4F2-TT与VKORC1-AA者大出血风险显著增高(HR 6.7,95%CI 1.5-29.8)。
- 多变异携带者中大出血病例数很少,相关结果需谨慎解读。
核心结论
- CYP4F2多态性与VKA治疗中大出血相关,尤其与VKORC1基因变异联合时风险显著增高。
- 上述基因变异可考虑用于进一步个体化抗凝治疗。
研究设计与样本
- 在BLEEDS队列(2012至2014年起始VKA的16,570例患者)内建立病例-队列研究。
- 选取随访17,613人年期间发生的全部326例大出血病例及978例随机亚队列患者。
- 检测CYP2C9、CYP4F2、GGCX、VKORC1变异,采用加权Cox回归估计大出血的风险比及95%CI。
- 最终在256例病例和783例亚队列成员中完成基因型测定。
主要发现
- 病例与亚队列中最常处方的VKA均为苯丙香豆素(分别占78%和75%)。
- CYP4F2-TT携带者较CC等位基因携带者大出血风险升高1.6倍(95%CI 0.9-2.8),但未达统计学显著。
- CYP2C9和GGCX变异与大出血风险关联接近无效值。
- 携带CYP2C9慢代谢型、CYP4F2-TT和VKORC1-AA中至少两种变异基因型者大出血风险升高4.0倍(95%CI 1.4-11.4)。
- 同时携带CYP4F2-TT与VKORC1-AA者较CYP4F2-CC且VKORC1-GG者大出血风险显著增高(HR 6.7,95%CI 1.5-29.8),但多变异携带者中大出血病例数很少(分别为8例和5例)。
临床怎么用
- 对VKA使用者可考虑检测CYP4F2与VKORC1基因型以辅助识别大出血高风险患者。
- 多变异携带者的大出血风险估计基于极少数病例,临床决策时应结合其他出血危险因素综合判断。
局限性
- 携带多种变异基因型的大出血病例数很少(分别为8例和5例),相关风险估计的精确性有限。
- CYP4F2-TT与大出血的关联未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major bleeding occurs annually in 1%-3% of patients on vitamin K antagonists (VKAs), despite close monitoring. Genetic variants in proteins involved in VKA response may affect this risk. AIM: To determine the association of genetic variants (cytochrome P450 enzymes 2C9 [CYP2C9] and 4F2 [CYP4F2], gamma-glutamyl carboxylase [GGCX]) with major bleeding in VKA users, separately and combined, including vitamin K epoxide reductase complex subunit-1 (VKORC1). METHODS: A case-cohort study was established within the BLEEDS cohort, which includes 16,570 patients who initiated VKAs between 2012 and 2014. We selected all 326 major bleeding cases that occurred during 17,613 years of follow-up and a random subcohort of 978 patients. We determined variants in CYP2C9, CYP4F2, GGCX, VKORC1 and evaluated the interaction between variant genotypes. Hazard ratios for major bleeding with 95% confidence intervals (95% CI) were estimated by weighted Cox regression. RESULTS: Genotype was determined in 256 cases and 783 subcohort members. Phenprocoumon was the most prescribed VKA for both cases and the subcohort (78% and 75%, respectively). Patients with major bleeding were slightly older than subcohort patients. CYP4F2-TT carriership was associated with a 1.6-fold (95% CI 0.9-2.8) increased risk of major bleeding compared with CC-alleles, albeit not statistically significant. For the CYP2C9 and GGCX variants instead, the major bleeding risk was around unity. Carrying at least two variant genotypes in CYP2C9 (poor metabolizer), CYP4F2-TT, and VKORC1-AA was associated with a 4.0-fold (95%CI 1.4-11.4) increased risk, while carriers of both CYP4F2-TT and VKORC1-AA had a particularly increased major bleeding risk (hazard ratio 6.7, 95% CI 1.5-29.8) compared with carriers of CC alleles in CYP4F2 and GG in VKORC1. However, the number of major bleeding cases in carriers of multiple variants was few (8 and 5 patients, respectively). CONCLUSIONS: CYP4F2 polymorphism was associated with major bleeding, especially in combination with VKORC1 genetic variants. These variants could be considered to further personalize anticoagulant treatment.
引用
- Camilleri E, Ghobreyal M, Bos MHA, et al. Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort. Pharmacotherapy. 2024. PMID: 38686648. doi:10.1002/phar.2923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。